Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
PRONOSTIC AND THERAPEUTIC CONSEQUENCES OF G(S)ALPHA MUTATIONS IN SOMATOTROPH ADENOMAS
Autore:
BARLIER A; GUNZ G; ZAMORA AJ; MORANGERAMOS I; FIGARELLABRANGER D; DUFOUR H; ENJALBERT A; JAQUET P;
Indirizzi:
UNIV MEDITERRANEE,FAC MED NORD,INST FEDERAT JEAN ROCHE,LAB ICNE,CNRS,UMR 6544,BLVD P DRAMARD F-13916 MARSEILLE 20 FRANCE CHU TIMONE,SERV ENDOCRINOL MARSEILLE FRANCE CHU TIMONE,LAB PATHOL & NEUROPATHOL MARSEILLE FRANCE CHU TIMONE,SERV NEUROCHIRURG MARSEILLE FRANCE
Titolo Testata:
The Journal of clinical endocrinology and metabolism
fascicolo: 5, volume: 83, anno: 1998,
pagine: 1604 - 1610
SICI:
0021-972X(1998)83:5<1604:PATCOG>2.0.ZU;2-B
Fonte:
ISI
Lingua:
ENG
Soggetto:
SECRETING PITUITARY-ADENOMAS; MCCUNE-ALBRIGHT SYNDROME; HUMAN ENDOCRINE TUMORS; ACROMEGALIC PATIENTS; BIOCHEMICAL CHARACTERISTICS; PROTEIN MUTATIONS; ADENYLYL CYCLASE; HORMONE; GS; OCTREOTIDE;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
32
Recensione:
Indirizzi per estratti:
Citazione:
A. Barlier et al., "PRONOSTIC AND THERAPEUTIC CONSEQUENCES OF G(S)ALPHA MUTATIONS IN SOMATOTROPH ADENOMAS", The Journal of clinical endocrinology and metabolism, 83(5), 1998, pp. 1604-1610

Abstract

Human pituitary somatotroph adenomas can be associated with mutationsof the (s) alpha-subunit of G proteins. However, the impact of the gsp mutations on the tumoral phenotype is not well understood at present. This study aims to determine whether the detection of this mutation could impact on the management of acromegalic patients. We examined 30acromegalic patients; 8 were gsp positive, and 22 were gsp negative. The gsp-positive adenomas appeared to secrete significantly more when the ratio of basal GH level/tumor size was considered. A better octreotide sensitivity of mutated adenomas was clearly shown under in vivo (short and long term) and in vitro conditions. During the acute octreotide test, the GH nadir was significantly lower in the gsp-positive adenomas (85% of maximal inhibition us. 52%). Eighteen patients were treated with octreotide (300 mu g/day) for at least 3 months before surgery: the percent inhibition of GPI hypersecretion was higher in gsp-positive adenomas (76% vs. 47%). In cell culture, the octreotide-induced inhibition of GH release was significantly higher in gsp-positive adenomas (71% vs. 30%). Finally, during 2 yr of postoperative follow-up, GHhypersecretion was controlled in all patients with gsp mutation even in those in whom tumoral tissue remained after surgery. On the contrary, in the gsp-negative group, octreotide treatment was unable to control hypersecretion in 4 patients bearing tumoral remnants. The G(s) alpha mutation could, therefore, be a new marker to foresee the susceptibility of the tumor to be controlled by somatostatin analogs, which improves prognosis.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 30/11/20 alle ore 07:16:42